- Home
- BHC vs KYMR Comparison
BHC vs KYMR Comparison
Compare BHC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- KYMR
- Stock Information
- Founded
- BHC N/A
- KYMR 2015
- Country
- BHC Canada
- KYMR United States
- Employees
- BHC N/A
- KYMR N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- BHC Health Care
- KYMR Health Care
- Exchange
- BHC Nasdaq
- KYMR Nasdaq
- Market Cap
- BHC 2.6B
- KYMR 2.2B
- IPO Year
- BHC N/A
- KYMR 2020
- Fundamental
- Price
- BHC $5.10
- KYMR $25.97
- Analyst Decision
- BHC Hold
- KYMR Buy
- Analyst Count
- BHC 5
- KYMR 13
- Target Price
- BHC $7.20
- KYMR $56.69
- AVG Volume (30 Days)
- BHC 3.0M
- KYMR 847.3K
- Earning Date
- BHC 04-30-2025
- KYMR 05-01-2025
- Dividend Yield
- BHC N/A
- KYMR N/A
- EPS Growth
- BHC N/A
- KYMR N/A
- EPS
- BHC N/A
- KYMR N/A
- Revenue
- BHC $9,625,000,000.00
- KYMR $47,072,000.00
- Revenue This Year
- BHC $4.76
- KYMR $16.24
- Revenue Next Year
- BHC $2.05
- KYMR $22.41
- P/E Ratio
- BHC N/A
- KYMR N/A
- Revenue Growth
- BHC 9.91
- KYMR N/A
- 52 Week Low
- BHC $3.96
- KYMR $19.45
- 52 Week High
- BHC $9.85
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- BHC 39.07
- KYMR 44.70
- Support Level
- BHC $4.28
- KYMR $24.43
- Resistance Level
- BHC $5.45
- KYMR $26.06
- Average True Range (ATR)
- BHC 0.41
- KYMR 2.36
- MACD
- BHC -0.06
- KYMR 0.41
- Stochastic Oscillator
- BHC 37.44
- KYMR 70.12
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.